Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q74552352)
Watch
English
Systemic therapy in melanoma
scientific article published on 01 June 1998
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Systemic therapy in melanoma
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
main subject
systemic therapy
1 reference
based on heuristic
inferred from title
author name string
F E Nathan
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
M J Mastrangelo
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
publication date
1 June 1998
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
published in
Journal of Surgical Oncology
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
volume
14
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
issue
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
page(s)
319-327
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
cites work
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Phase II trial of fotemustine in patients with metastatic malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Vindesine as a single agent in the treatment of advanced malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
A multicentre phase II trial of vindesine in malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
EORTC phase II trial of vindesine in advanced melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Taxol stabilizes microtubules in mouse fibroblast cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Fotemustine plus dacarbazine for malignant melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Fotemustine plus dacarbazine in advanced stage III malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Combination chemotherapy of metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Effective chemotherapy for melanoma after treatment with interleukin-2
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
[Alpha 2 -interferon therapy in metastasizing malignant melanoma]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Intralesional interferon-alpha therapy in advanced malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Interleukin-2 toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Sequential chemoimmunotherapy in the treatment of metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Dose: a critical factor in cancer chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199806%2914%3A4%3C319%3A%3AAID-SSU8%3E3.0.CO%3B2-5
retrieved
21 January 2018
Identifiers
DOI
10.1002/(SICI)1098-2388(199806)14:4<319::AID-SSU8>3.0.CO;2-5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
PubMed publication ID
9588725
1 reference
stated in
Europe PubMed Central
PubMed publication ID
9588725
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9588725%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit